Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study

<p>This study aimed to investigate the effectiveness and safety of Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) in the real world. All consecutive patients with RA from the KEIO-RA cohort who had received a JAKi from July 2013 to June 2023 were included. We assess...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Satoshi Takanashi (15221350) (author)
Altres autors:	Masatoshi Kawai (2074750) (author), Mitsuhiro Akiyama (3412106) (author), Yasushi Kondo (371654) (author), Shuntaro Saito (4519816) (author), Masaru Takeshita (6197132) (author), Jun Kikuchi (266172) (author), Hironari Hanaoka (3910738) (author), Yuko Kaneko (839653) (author)
Publicat:	2025
Matèries:	Biochemistry Medicine Pharmacology Biotechnology Ecology Immunology Developmental Biology Science Policy Chemical Sciences not elsewhere classified Rheumatoid arthritis JAK inhibitors difficult-to-treat rheumatoid arthritis retention rates effectiveness safety
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study

Ítems similars